Therapeutic Development Using Chemically Modified Asymmetric siRNAs

Time: 9:00 am

Details:

  • Asymmetric siRNA (asiRNA) triggers efficient target gene silencing with reduced non-specific effects
  • OliX has developed cp-asiRNA for local administration therapeutics, and GalNAc-asiRNA for liver targeting therapeutics
  • Describing OliX Pharmaceuticals’ pre-clinical and clinical developments against various disease indications

Speakers: